C
Camurus
Sustainability Report and Carbon Intensity Rankings
Is Camurus doing their part?
Their DitchCarbon score is 48
Camurus has a DitchCarbon Score of 48 out of 100, indicating moderate performance in sustainability practices. This score reflects the company’s current carbon intensity level, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing environmental sustainability.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Camurus is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Camurus is located in Sweden, a country with a very low carbon intensity rating. This suggests that the company’s operations benefit from the nation’s strong sustainability efforts and clean energy usage.
Unlock 30+ emissions data points on Camurus
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Camurus
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
6.71%
...this company is doing 6.71% better in emissions than the industry average.
Camurus, founded in 1991, is a Swedish pharmaceutical company located in Lund, operating within the industrial manufacturing sector. The company specializes in developing and commercializing innovative medicines for severe and chronic conditions, utilizing its proprietary FluidCrystal drug delivery technologies. Camurus maintains a clinical pipeline that addresses cancer, endocrine diseases, pain, and addiction, and is publicly traded on Nasdaq Stockholm.
emission intelligence's platform recommendations for Camurus
Camurus should foster partnerships with industry peers to exchange best practices and resources, enhancing their collective ability to diminish Scope 3 emissions.
Bad news, Camurus hasn't committed to SBTi goals yet
Camurus has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not defined or announced clear goals for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.